MARIETTA, Ga., April 5, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine and
The clinical and cost effective healing results of the Company's dehydrated Human Amnion/Chorion Membrane (dHACM) allografts will be presented via four clinical poster presentations, in-booth education sessions, a breakfast symposium and a dinner presentation at the 2017 SAWC Spring/WHS meeting. The symposium is the leading national wound healing conference and is now in its 30th year. The 2017 SAWC Spring/WHS begins April 5, 2017, and concludes on April 9, 2017. MiMedx will be exhibiting in booth # 605 from April 6, 2017 through April 8, 2017.
Three of the four poster presentations will report on the clinical effectiveness of MiMedx EpiFix dHACM and AmnioFill placental tissue allografts in the healing of diabetic foot ulcers, chronic diabetic lower extremity ulcerated wounds, venous leg ulcers, refractory non-healing wounds, and hard to treat wounds. The fourth poster presentation will report on a unique surgical case involving EpiCord, the Company's new dehydrated human umbilical cord allograft, and its effectiveness in the treatment of a chronic lower extremity ulcer.
MiMedx will also sponsor a Breakfast Symposium entitled, "Addressing Acute, Complex and Chronic Wounds with EpiFix Dehydrated Human Amnion/Chorion Allografts and New Placental Tissue Products" on April 7, 2017 from 7:30am to 9:00am. Physician and study author Matthew Garoufalis, DPM, FASPS, FACFAOM, CWS, will chair the symposium.
In-booth education will be provided on April 6 and April 7, 2017 by two prominent physicians:
Windy Cole, DPM, will be the speaker at a dinner presentation on April 7 at 8:00 pm that focuses on both wound care and surgical applications of MiMedx dHACM allografts. Dr. Cole's presentation is entitled "The Use of EpiFix and AmnioFix for Acute and Chronic Wounds."
The poster presentations chronicling independent case studies and respective conclusions relative to MiMedx dHACM and Cord allografts include:
Parker H. "Pete" Petit, CEO, said, "We are always honored to be a part of the SAWC/WHS meeting. For 30 years, they have been dedicated to continuous advancements in wound care and have worked tirelessly toward their goal of decreasing the number and severity of wounds of all types. We continue to work with SAWC and other organizations to raise the level of scientific and clinical expertise and the professional processes within the wound care sector of healthcare."
Bill Taylor, President and COO of MiMedx, added, "We are pleased that our EpiFix, AmnioFix, EpiCord, AmnioCord, and AmnioFill allografts are so prominently demonstrated at this year's SAWC. We look forward to another very enlightening and educational symposium."
About MiMedxMiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biopharmaceutical and biomaterial products processed from donated placental tissues. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 800,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the significance of case study results. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that other case studies may have different or less favorable results, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2016. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-use-of-mimedx-allografts-from-the-companys-multiple-product-families-to-be-presented-at-sawc-conference-300435498.html
SOURCE MiMedx Group, Inc.
Subscribe to our Free Newsletters!
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All